Additional evidence revealed that patients benefited from the durvalumab regimen regardless of baseline BMs status, which suggested that PD‐L1 inhibitors contribute to improved survival in SCLC‐BMs patients.8 Here, CD274 is linked to small cell lung carcinoma.